

Europe In Vitro Diagnostics Market by Product & Service(Chemicals & Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care, and Others): Opportunity Analysis and Industry Forecast, 2020–2027

https://marketpublishers.com/r/E2EC265606C7EN.html

Date: June 2020

Pages: 289

Price: US\$ 4,249.00 (Single User License)

ID: E2EC265606C7EN

Abstracts

The Europe in vitro diagnostics market (IVD) was valued at \$13,825 million in 2019, and is projected to reach \$18,647 million at a CAGR of 4.8% from 2020 to 2027.

In vitro diagnostics (IVD) are defined as medical devices and reagents, which are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections. The tests can be performed in standalone laboratory, hospital-based laboratory, and point-of-care centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Moreover, other techniques that are used to perform in vitro diagnosis involve clinical chemistry, tissue



diagnostics, immunodiagnostics, hematology, and others. For instance, in clinical chemistry various tests are performed in laboratory such as liver panel test, lipid profile, thyroid function test, and others.

Furthermore, a thyroid function test is performed by collecting blood from a patient, which is then tested to check the level of thyroid stimulating hormone (TSH) in blood. Similarly, others such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV and hepatitis. In addition, constant innovations related to IVD products, service designs, and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. For instance, some products that are used to perform various in vitro diagnostic tests using various technologies involve real time PCR detection systems, immunoassay systems, and others.

The major factor that contributes to the growth of the Europe in vitro diagnostic market include surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels the growth of the market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict the growth of the Europe in vitro diagnostics market. On the contrary, potential for outsourcing present lucrative opportunities for key players in the Europe in vitro diagnostics market during the forecast period.

The report segments the market into product & service, technique, application, end user, and region. On the basis of product & service, it is segmented into chemicals & reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.



On the basis of application, the market is segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Country wise, the market is analyzed across Germany, France, the UK, Italy, Spain, and rest of Europe.

The major players in the in vitro diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, bioM?rieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current Europe in vitro diagnostics market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Product & Service

Chemicals & Reagents

Instruments

Software and Services



By Technique		
Immunodiagnostics		
Enzyme-Linked Immunosorbent Assay (ELISA)		
Chemiluminescence Immunoassay (CLIA)		
Fluorescence immunoassay (FIA)		
Colorimetric Immunoassay (CI)		
Rapid Tests		
Enzyme-Linked ImmunoSpot (ELISPOT)		
Radioimmunoassay (RIA)		
Western Blot		
Hematology		
Molecular Diagnostics		
Polymerize Chain Reaction (PCR)		
Isothermal Nucleic Acid Amplification Technology (INAAT)		
Hybridization		
DNA diagnostics		
Microarray		
Others		

Tissue Diagnostics



Clinical Chemistry

	·	
	Basic Metabolic Panel	
	Liver Panel	
	Lipid Profile	
	Thyroid Function Panel	
	Electrolyte Panel	
	Specialty Chemicals	
	Others	
By Application		
	Infectious Diseases	
	Cancer	
	Cardiac Diseases	
	Immune System Disorders	
	Nephrological Diseases	
	Gastrointestinal Diseases	
	Others	
By End User		
	Standalone Laboratories	
	Hospitals	
	Academic & Medical Schools	



Point-of-Care		
Others		
By Country		
Germany		
France		
UK		
Italy		
Spain		
Rest of Europe		
List of key players profiled in the report:		
Abbott Laboratories		
Becton, Dickinson and Company		
bioM?rieux SA		
Bio-Rad Laboratories, Inc.		
Danaher Corporation (Beckman Coulter, Inc.)		
F. Hoffmann-La Roche AG		
Siemens AG		
QIAGEN N.V.		
Sysmex Corporation		



Thermo Fisher Scientific, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

DiaSorin

Johnson & Johnson



Contents

CHAPTER 1: INTRODUCTION

- 1.1.Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
- 1.3.1.List of key players profiled in the report
- 1.4.Research methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. Key findings of the study
- 2.2.CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3. Top winning strategies, 2019
- 3.4. Market Share Analysis, 2019
- 3.5. Porters five forces analysis
- 3.6.Market dynamics
 - 3.6.1.Drivers
 - 3.6.1.1.Increase in incidences of chronic and infectious diseases
 - 3.6.1.2. Technological advancements in IVD
 - 3.6.1.3. Rise in adoption of in vitro diagnostic testing
 - 3.6.1.4. Rise in geriatric population
 - 3.6.1.5. Increase in popularity of personalized medicine approach
 - 3.6.2.Restraint
 - 3.6.2.1. Unclear reimbursement policies
 - 3.6.2.2. Stringent regulatory policies
 - 3.6.3. Opportunity
 - 3.6.3.1. Potential opportunities for outsourcing
 - 3.6.4.Impact Analysis



3.7.COVID-19 Impact Analysis

CHAPTER 4: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

- 4.1.Overview
 - 4.1.1.Market size and forecast
- 4.2.Chemicals & Reagents
 - 4.2.1. Key market trends, growth factors, and opportunities
 - 4.2.2. Market size and forecast, by country
 - 4.2.3. Market share analysis, by country
- 4.3.Instruments
 - 4.3.1. Key market trends, growth factors, and opportunities
 - 4.3.2. Market size and forecast, by country
 - 4.3.3. Market share analysis, by country
- 4.4.Software & Services
 - 4.4.1. Key market trends, growth factors, and opportunities
 - 4.4.2. Market size and forecast, by country
 - 4.4.3. Market share analysis, by country

CHAPTER 5: IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

- 5.1.Overview
 - 5.1.1.Market size and forecast
- 5.2.Immunodiagnostics
 - 5.2.1. Key market trends, growth factors, and opportunities
 - 5.2.2. Market size and forecast, by country
 - 5.2.3. Market share analysis, by country
 - 5.2.4. Market size and forecast, by type
 - 5.2.4.1.Enzyme-linked immunosorbent assay (ELISA)
 - 5.2.4.1.1.Market size and forecast, by type
 - 5.2.4.1.2. Chemiluminescence Immunoassay (CLIA)
 - 5.2.4.1.2.1.Market size and forecast
 - 5.2.4.1.3.Fluorescence immunoassay (FIA)
 - 5.2.4.1.3.1. Market size and forecast
 - 5.2.4.1.4.Colorimetric Immunoassay (CI)
 - 5.2.4.1.4.1.Market size and forecast
 - 5.2.4.2.Rapid Tests
 - 5.2.4.2.1.Market size and forecast
 - 5.2.4.3. Enzyme-linked immunospot (ELISPOT)



- 5.2.4.3.1.Market size and forecast
- 5.2.4.4.Radioimmunoassay (RIA)
 - 5.2.4.4.1.Market size and forecast
- 5.2.4.5.Western blot
 - 5.2.4.5.1. Market size and forecast
- 5.3. Hematology
 - 5.3.1. Key market trends, growth factors, and opportunities
 - 5.3.2. Market size and forecast, by country
 - 5.3.3. Market share analysis, by country
- 5.4. Molecular diagnostics
 - 5.4.1. Key market trends, growth factors, and opportunities
 - 5.4.2. Market size and forecast, by country
 - 5.4.3. Market share analysis, by country
 - 5.4.4. Market size and forecast, by type
 - 5.4.4.1.Polymerize chain reaction (PCR)
 - 5.4.4.1.1.Market size and forecast
 - 5.4.4.2. Isothermal Nucleic acid amplification technology (INAAT)
 - 5.4.4.2.1.Market size and forecast
 - 5.4.4.3. Hybridization
 - 5.4.4.3.1. Market size and forecast
 - 5.4.4.4.DNA diagnostics
 - 5.4.4.4.1. Market size and forecast
 - 5.4.4.5.Microarray
 - 5.4.4.5.1.Market size and forecast
 - 5.4.4.6.Others
 - 5.4.4.6.1.Market size and forecast
- 5.5. Tissue diagnostics
 - 5.5.1. Key market trends, growth factors, and opportunities
 - 5.5.2. Market size and forecast, by country
 - 5.5.3. Market share analysis, by country
- 5.6. Clinical chemistry
 - 5.6.1. Key market trends, growth factors, and opportunities
 - 5.6.2. Market size and forecast, by country
 - 5.6.3. Market share analysis, by country
 - 5.6.4. Market size and forecast, by type
 - 5.6.4.1. Basic metabolic panel
 - 5.6.4.1.1.Market size and forecast
 - 5.6.4.2.Liver panel
 - 5.6.4.2.1.Market size and forecast



- 5.6.4.3. Renal profile
 - 5.6.4.3.1.Market size and forecast
- 5.6.4.4.Lipid profile
 - 5.6.4.4.1. Market size and forecast
- 5.6.4.5. Thyroid function panel
 - 5.6.4.5.1. Market size and forecast
- 5.6.4.6. Electrolyte panel
 - 5.6.4.6.1. Market size and forecast
- 5.6.4.7. Specialty chemicals
 - 5.6.4.7.1.Market size and forecast
- 5.7.Others
 - 5.7.1. Key market trends, growth factors, and opportunities
 - 5.7.2. Market size and forecast, by country
 - 5.7.3. Market share analysis, by country

CHAPTER 6: IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

- 6.1. Overview
 - 6.1.1.Market size and forecast
- 6.2.Infectious Diseases
 - 6.2.1. Key market trends, growth factors, and opportunities
 - 6.2.2. Market size and forecast, by country
 - 6.2.3. Market share analysis, by country
- 6.3.Cancer
 - 6.3.1. Key market trends, growth factors, and opportunities
 - 6.3.2. Market size and forecast, by country
 - 6.3.3. Market share analysis, by country
- 6.4. Cardiac diseases
 - 6.4.1. Key market trends, growth factors, and opportunities
 - 6.4.2. Market size and forecast, by country
 - 6.4.3. Market share analysis, by country
- 6.5.Immune system disorders
 - 6.5.1. Key market trends, growth factors, and opportunities
 - 6.5.2. Market size and forecast, by country
 - 6.5.3. Market share analysis, by country
- 6.6. Nephrological diseases
 - 6.6.1. Key market trends, growth factors, and opportunities
 - 6.6.2. Market size and forecast, by country
 - 6.6.3. Market share analysis, by country



- 6.7. Gastrointestinal diseases
- 6.7.1. Key market trends, growth factors, and opportunities
- 6.7.2. Market size and forecast, by country
- 6.7.3. Market share analysis, by country
- 6.8.Others
 - 6.8.1. Key market trends, growth factors, and opportunities
 - 6.8.2. Market size and forecast, by country
 - 6.8.3. Market share analysis, by country

CHAPTER 7: IN VITRO DIAGNOSTICS MARKET, BY END USER

- 7.1.Overview
 - 7.1.1.Market size and forecast
- 7.2. Standalone Laboratories
 - 7.2.1. Key market trends, growth factors, and opportunities
 - 7.2.2.Market size and forecast, by country
 - 7.2.3. Market share analysis, by country
- 7.3. Hospitals
 - 7.3.1. Key market trends, growth factors, and opportunities
 - 7.3.2. Market size and forecast, by country
 - 7.3.3. Market share analysis, by country
- 7.4. Academic and medical schools
 - 7.4.1. Key market trends, growth factors, and opportunities
 - 7.4.2. Market size and forecast, by country
 - 7.4.3. Market share analysis, by country
- 7.5.Point-of-care testing
 - 7.5.1. Key market trends, growth factors, and opportunities
 - 7.5.2. Market size and forecast, by country
 - 7.5.3. Market share analysis, by country
- 7.6.Others
 - 7.6.1. Key market trends, growth factors, and opportunities
 - 7.6.2. Market size and forecast, by country
 - 7.6.3. Market share analysis, by country

CHAPTER 8: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY

- 8.1.Overview
 - 8.1.1. Key market trends, growth factors, and opportunities
 - 8.1.2. Market size and forecast, by country



- 8.1.2.1.Germany
- 8.1.2.2.Market size and forecast
 - 8.1.2.2.1.Germany in vitro diagnostics market, by product & service
 - 8.1.2.2.2.Germany In vitro diagnostics market, by technique
- 8.1.2.2.3. Germany In vitro diagnostics market, by application
- 8.1.2.2.4. Germany In vitro diagnostics market, by end user
- 8.1.2.3.France
- 8.1.2.4. Market size and forecast
 - 8.1.2.4.1. France In vitro diagnostics market, by product & service
 - 8.1.2.4.2. France In vitro diagnostics market, by technique
 - 8.1.2.4.3. France In vitro diagnostics market, by application
 - 8.1.2.4.4. France In vitro diagnostics market, by end user
- 8.1.2.5.UK
- 8.1.2.6. Market size and forecast
 - 8.1.2.6.1.UK In vitro diagnostics market, by product & service
 - 8.1.2.6.2.UK In vitro diagnostics market, by technique
 - 8.1.2.6.3.UK In vitro diagnostics market, by application
 - 8.1.2.6.4.UK In vitro diagnostics market, by end user
- 8.1.2.7.Italy
- 8.1.2.8. Market size and forecast
 - 8.1.2.8.1. Italy in vitro diagnostics market, by product & service
 - 8.1.2.8.2. Italy In vitro diagnostics market, by technique
- 8.1.2.8.3. Italy In vitro diagnostics market, by application
- 8.1.2.8.4. Italy In vitro diagnostics market, by end user
- 8.1.2.9.Spain
- 8.1.2.10.Market size and forecast
 - 8.1.2.10.1. Spain In vitro diagnostics market, by product & service
 - 8.1.2.10.2. Spain In vitro diagnostics market, by technique
 - 8.1.2.10.3. Spain In vitro diagnostics market, by application
- 8.1.2.10.4. Spain In vitro diagnostics market, by end user
- 8.1.2.11.Rest of Europe
- 8.1.2.12.Market size and forecast
 - 8.1.2.12.1. Rest of Europe In vitro diagnostics market, by product & service
 - 8.1.2.12.2.Rest of Europe In vitro diagnostics market, by technique
 - 8.1.2.12.3. Rest of Europe In vitro diagnostics market, by application
 - 8.1.2.12.4.Rest of Europe In vitro diagnostics market, by end user

CHAPTER 9: COMPANY PROFILES



9.1.ABBOTT LABORATORIES

- 9.1.1.Company overview
- 9.1.2.Company snapshot
- 9.1.3. Operating business segments
- 9.1.4. Product and service portfolio
- 9.1.5. Business performance
- 9.1.6. Key strategic moves and developments

9.2.BECTON, DICKINSON AND COMPANY

- 9.2.1.Company overview
- 9.2.2.Company snapshot
- 9.2.3. Operating business segments
- 9.2.4. Product and service portfolio
- 9.2.5. Business performance
- 9.2.6. Key strategic moves and developments

9.3.BIOM?RIEUX SA

- 9.3.1.Company overview
- 9.3.2.Company snapshot
- 9.3.3. Operating business segments
- 9.3.4. Product and service portfolio
- 9.3.5. Business performance
- 9.3.6. Key strategic moves and developments

9.4.BIO-RAD LABORATORIES, INC.

- 9.4.1.Company overview
- 9.4.2.Company snapshot
- 9.4.3. Operating business segments
- 9.4.4. Product and service portfolio
- 9.4.5. Business performance
- 9.4.6. Key strategic moves and developments

9.5. DANAHER CORPORATION (BECKMAN COULTER, INC.)

- 9.5.1.Company overview
- 9.5.2.Company snapshot
- 9.5.3. Operating business segments
- 9.5.4. Product and service portfolio
- 9.5.5. Business performance
- 9.5.6. Key strategic moves and developments
- 9.6.F. HOFFMANN-LA ROCHE AG.
 - 9.6.1.Company snapshot
 - 9.6.2. Operating business segments
 - 9.6.3. Product and service portfolio



- 9.6.4. Business performance
- 9.6.5. Key strategic moves and developments
- 9.7.QIAGEN N.V.
 - 9.7.1.Company overview
 - 9.7.2.Company snapshot
 - 9.7.3. Operating business segments
 - 9.7.4. Product and service portfolio
 - 9.7.5. Business performance
 - 9.7.6. Key strategic moves and developments
- 9.8. SIEMENS AG (SIEMENS HEALTHINEERS)
 - 9.8.1.Company overview
 - 9.8.2.Company snapshot
 - 9.8.3. Operating business segments
 - 9.8.4. Product portfolio
 - 9.8.5. Business performance
 - 9.8.6. Key strategic moves and developments
- 9.9.SYSMEX CORPORATION
 - 9.9.1.Company overview
 - 9.9.2.Company snapshot
 - 9.9.3. Operating business segments
 - 9.9.4. Product and service portfolio
 - 9.9.5.Business performance
- 9.10.THERMO FISHER SCIENTIFIC, INC.
 - 9.10.1.Company overview
 - 9.10.2.Company snapshot
 - 9.10.3. Operating business segments
 - 9.10.4. Product and service portfolio
 - 9.10.5. Business performance
 - 9.10.6. Key strategic moves and developments



List Of Tables

LIST OF TABLES

TABLE 01.ESTIMATED GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2018

TABLE 02.TYPES OF IN VITRO DIAGNOSTIC PRODUCTS AVAILABLE FOR COVID-19 DIAGNOSIS

TABLE 03.IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027 (\$MILLION)

TABLE 04.IN VITRO DIAGNOSTICS MARKET FOR CHEMICAL & REAGENTS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 05.IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 06.IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019–2027 (\$MILLION)

TABLE 07.IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 (\$MILLION)

TABLE 08.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 09.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2019–2027 (\$MILLION)

TABLE 10.IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY TYPE, 2019–2027 (\$MILLION)

TABLE 11.IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 12.IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 13.MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2019–2027 (\$MILLION) TABLE 14.IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 15.IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 16.CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2027 (\$MILLION) TABLE 17.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 18.IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 (\$MILLION)

TABLE 19.IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY



COUNTRY,2019-2027 (\$MILLION)

TABLE 20.IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY

COUNTRY,2019-2027 (\$MILLION)

TABLE 21.IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY,2019–2027 (\$MILLION)

TABLE 22.IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY,2019–2027 (\$MILLION)

TABLE 23.IN VITRO DIAGNOSTICS MARKET FOR NEPROLOGICAL DISEASES, BY COUNTRY,2019–2027 (\$MILLION)

TABLE 24.IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 25.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY,2019–2027 (\$MILLION)

TABLE 26.IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 (\$MILLION)

TABLE 27.IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 28.IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 29.IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 30.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 31.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 32.EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

TABLE 33.GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 34.GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027

TABLE 35.GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027

TABLE 36.GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 TABLE 37.FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 38.FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 TABLE 39.FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027



TABLE 40.FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 TABLE 41.UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 42.UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 TABLE 43.UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 TABLE 44.UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 TABLE 45.ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 46.ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 TABLE 47.ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 TABLE 48.ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 TABLE 49.SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 50.SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 TABLE 51.SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 TABLE 52.SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 TABLE 53.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027

TABLE 54.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027

TABLE 55.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027

TABLE 56.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027

TABLE 57.ABBOTT: COMPANY SNAPSHOT

TABLE 58.ABBOTT: OPERATING SEGMENTS

TABLE 59.ABBOTT: PRODUCT AND SERVICE PORTFOLIO

TABLE 60.BD: COMPANY SNAPSHOT

TABLE 61.BD: OPERATING SEGMENTS

TABLE 62.BD: PRODUCT AND SERVICE PORTFOLIO

TABLE 63.BIOM?RIEUX: COMPANY SNAPSHOT

TABLE 64.BIOM?RIEUX: OPERATING SEGMENTS

TABLE 65.BIOM?RIEUX: PRODUCT AND SERVICE PORTFOLIO

TABLE 66.BIO-RAD: COMPANY SNAPSHOT

TABLE 67.BIO-RAD: OPERATING SEGMENTS

TABLE 68.BIO-RAD: PRODUCT AND SERVICE PORTFOLIO

TABLE 69.DANAHER: COMPANY SNAPSHOT

TABLE 70.DANAHER: OPERATING SEGMENTS

TABLE 71.DANAHER: PRODUCT AND SERVICE PORTFOLIO



TABLE 72.ROCHE: COMPANY SNAPSHOT

TABLE 73.ROCHE: OPERATING SEGMENTS

TABLE 74.ROCHE: PRODUCT AND SERVICE PORTFOLIO

TABLE 75.QIAGEN: COMPANY SNAPSHOT

TABLE 76.QIAGEN: OPERATING SEGMENTS

TABLE 77.QIAGEN: PRODUCT AND SERVICE PORTFOLIO

TABLE 78. SIEMENS: COMPANY SNAPSHOT

TABLE 79. SIEMENS: OPERATING SEGMENTS

TABLE 80. SIEMENS: PRODUCT PORTFOLIO

TABLE 81.SYSMEX: COMPANY SNAPSHOT

TABLE 82.SYSMEX: OPERATING SEGMENTS

TABLE 83.SYSMEX: PRODUCT AND SERVICE PORTFOLIO

TABLE 84.THERMO FISHER: COMPANY SNAPSHOT

TABLE 85.THERMO FISHER: OPERATING SEGMENTS

TABLE 86.THERMO FISHER SCIENTIFIC: PRODUCT AND SERVICE PORTFOLIO



List Of Figures

LIST OF FIGURES

FIGURE 01.IN-VITRO DIAGNOSTICS MARKET SEGMENTATION

FIGURE 02.TECHNIQUE MARKET SUB-SEGMENTATION

FIGURE 03.TOP INVESTMENT POCKETS

FIGURE 04.TOP WINNING STRATEGIES, 2017–2020

FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020

FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017-2020

FIGURE 07.MARKET SHARE ANALYSIS, 2019

FIGURE 08.BARGANING POWER OF BUYERS

FIGURE 09.BARGANING POWER OF SUPPLIERS

FIGURE 10.THREAT OF SUBSTITUTIONS

FIGURE 11.THREAT OF NEW ENTRANTS

FIGURE 12.MODERATE COMPETITIVE RIVALRY

FIGURE 13.IMPACT ANALYSIS, IN-VITRO DIAGNOSTICS MARKET

FIGURE 14.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR

CHEMICALS & REAGENTS, BY COUNTRY, 2019 & 2027

FIGURE 15.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR

INSTRUMENTS, BY COUNTRY, 2019 & 2027

FIGURE 16.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2019 & 2027

FIGURE 17.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019 & 2027

FIGURE 18.IMMUNODIAGNOSTICS MARKET FOR ENZYME LINKED

IMMUNOSORBENT ASSAY, 2019–2027 (\$MILLION)

FIGURE 19.IMMUNODIAGNOSTICS MARKET FOR RAPID TESTS, 2019–2027 (\$MILLION)

FIGURE 20.IMMUNODIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT (ELISPOT), 2019–2027 (\$MILLION)

FIGURE 21.IMMUNODIAGNOSTICS MARKET FOR RADIOIMMUNOASSAY (RIA), 2019–2027 (\$MILLION)

FIGURE 22.IMMUNODIAGNOSTICS MARKET FOR WESTERN BLOT, 2019–2027 (\$MILLION)

FIGURE 23.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019 & 2027

FIGURE 24.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027



FIGURE 25.MOLECULAR DIAGNOSTICS MARKET FOR POLYMERIZE CHAIN REACTION (PCR), 2019–2027 (\$MILLION)

FIGURE 26.MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), 2019–2027 (\$MILLION)

FIGURE 27.MOLECULAR DIAGNOSTICS MARKET FOR HYBRIDIZATION, 2019–2027 (\$MILLION)

FIGURE 28.MOLECULAR DIAGNOSTICS MARKET FOR DNA DIAGNOSTICS, 2019–2027 (\$MILLION)

FIGURE 29.MOLECULAR DIAGNOSTICS MARKET FOR MICROARRAY, 2019–2027 (\$MILLION)

FIGURE 30.MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, 2019–2027 (\$MILLION)

FIGURE 31.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019 & 2027

FIGURE 32.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019 & 2027

FIGURE 33.CLINICAL CHEMISTRY MARKET FOR BASIC METABOLIC PANEL, 2019–2027 (\$MILLION)

FIGURE 34.CLINICAL CHEMISTRY MARKET FOR LIVER PANEL, 2019–2027 (\$MILLION)

FIGURE 35.CLINICAL CHEMISTRY MARKET FOR RENAL PROFILE, 2019–2027 (\$MILLION)

FIGURE 36.CLINICAL CHEMISTRY MARKET FOR LIPID PROFILE, 2019–2027 (\$MILLION)

FIGURE 37.CLINICAL CHEMISTRY MARKET FOR THYROID FUNCTION PANEL, 2019–2027 (\$MILLION)

FIGURE 38.CLINICAL CHEMISTRY MARKET FOR ELECTROLYTE PANEL, 2019–2027 (\$MILLION)

FIGURE 39.CLINICAL CHEMISTRY MARKET FOR SPECIALTY CHEMICALS, 2019–2027 (\$MILLION)

FIGURE 40.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027

FIGURE 41.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019 & 2027

FIGURE 42.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2019 & 2027

FIGURE 43.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY, 2019 & 2027

FIGURE 44.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR



IMMUNE SYSTEM DISORDERS, BY COUNTRY, 2019 & 2027

FIGURE 45.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019 & 2027

FIGURE 46.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027

FIGURE 47.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027

FIGURE 48.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES. BY COUNTRY, 2019 & 2027

FIGURE 49.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027

FIGURE 50.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019 & 2027

FIGURE 51.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027

FIGURE 52.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027

FIGURE 53.GERMANY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 54.FRANCE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 55.UK. IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 56.ITALY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 57.SPAIN IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 58.REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 59.ABBOTT: NET SALES, 2017–2019 (\$MILLION)

FIGURE 60.ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2019 (%)

FIGURE 61.ABBOTT: NET SALES SHARE, BY REGION, 2019 (%)

FIGURE 62.BD: REVENUE, 2017–2019 (\$MILLION)

FIGURE 63.BD: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 64.BD: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 65.BIOM?RIEUX: NET SALES, 2016–2018 (\$MILLION)

FIGURE 66.BIOM?RIEUX: REVENUE SHARE, BY SEGMENT, 2018 (%)

FIGURE 67.BIOM?RIEUX: REVENUE SHARE, BY REGION, 2018 (%)

FIGURE 68.BIO-RAD: NET SALES, 2017-2019 (\$MILLION)

FIGURE 69.BIO-RAD: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 70.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 71.DANAHER: NET SALES, 2017-2019 (\$MILLION)

FIGURE 72.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 73.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)



FIGURE 74.ROCHE: NET SALES, 2017-2019 (\$MILLION)

FIGURE 75.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 76.QIAGEN: NET SALES, 2017–2019 (\$MILLION)

FIGURE 77. QIAGEN: REVENUE SHARE, BY PRODUCT AND SERVICE, 2019 (%)

FIGURE 78.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 79.NET SALES, 2017–2019 (\$MILLION)

FIGURE 80. SIEMENS: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 81.SIEMENS: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 82.SYSMEX: REVENUE, 2017–2019 (\$MILLION)

FIGURE 83.SYSMEX: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 84.SYSMEX: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 85.THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 (\$MILLION)

FIGURE 86.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018

(%)

FIGURE 87.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2018 (%)

COMPANIES MENTIONED

Abbott Laboratories, Becton, Dickinson and Company, bioM?rieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.



I would like to order

Product name: Europe In Vitro Diagnostics Market by Product & Service(Chemicals & Reagents,

Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application

(Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care, and

Others): Opportunity Analysis and Industry Forecast, 2020–2027

Product link: https://marketpublishers.com/r/E2EC265606C7EN.html

Price: US\$ 4,249.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/E2EC265606C7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature



Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$